Yazılar

Shopify Reports Strong Holiday Sales, But Profit Outlook Disappoints

/in /tarafından

Shopify (SHOP.TO) experienced its strongest quarterly revenue growth in three years on Tuesday, driven by robust consumer spending and the company’s integration of AI features aimed at supporting its sellers. The Canadian e-commerce giant reported a 31% year-over-year revenue increase, reaching $2.81 billion for the fourth quarter, surpassing analysts’ expectations of $2.73 billion.

The company’s success was fueled by strong holiday sales and the launch of its AI-driven tools, known as ‘Shopify Magic,’ which assist merchants with tasks such as inventory management and image generation. These AI tools are available to all subscription tiers for free, further attracting merchants to the platform.

Despite the strong revenue growth, Shopify’s shares fell approximately 2% in early trading. Investors expressed concerns over the company’s weaker-than-expected profit forecast for the current quarter. The company’s high investments in technology, marketing, and global expansion, coupled with rising cloud and infrastructure hosting costs, have led to concerns about margin growth.

Shopify’s CFO, Jeff Hoffmeister, acknowledged that while these costs may not significantly impact future quarters, the company plans to continue investing heavily in research and development. This expansion strategy includes venturing into new markets, which, while promising, could put pressure on profitability in the short term.

The company’s forecast for gross profit growth in the current quarter—projected to be in the low-twenties percentage range—falls below analysts’ expectations of a 24.2% increase. Additionally, Shopify’s forecast for operating expenses as a percentage of revenue, which is expected to be between 41% and 42%, also exceeded analysts’ expectations, further contributing to investor concerns about potential profitability challenges.

Ford Cuts Profit Outlook, Faces Stock Drop

/in /tarafından

Ford Motor Co. announced on Monday that it now anticipates meeting only the lower end of its full-year profit expectations, leading to a 5% dip in after-hours stock trading. The automaker forecasts annual earnings before interest and taxes (EBIT) around $10 billion, down from the previous $10-12 billion target.

Financial Performance and EV Adjustments

Despite its weakened forecast, Ford’s third-quarter earnings came in slightly better than expected, with adjusted profits of $0.49 per share compared to analysts’ projections of $0.47. However, net income dropped to $900 million, or $0.22 per share, from $0.30 per share a year ago, influenced by a $1 billion charge incurred after the cancellation of a three-row electric SUV in August.

CEO Jim Farley’s strategic cutbacks in Ford’s electric vehicle (EV) segment reflect intensified competition from Tesla and emerging Chinese EV brands. The scrapped three-row EV, once projected as a “personal bullet train,” was ultimately deemed unprofitable within the necessary timeframe for EV business sustainability.

EV Losses and Cost-Cutting Initiatives

Ford’s electric vehicle segment is projected to incur a $5 billion loss this year, with an EBIT loss of $1.2 billion in the third quarter alone, raising the segment’s total loss for 2024’s first three quarters to $3.7 billion. Although the company made cost improvements totaling nearly $1 billion over the past year, industry-wide pricing pressures have limited visible gains.

Looking ahead, Ford remains committed to cutting $2 billion in annual expenses by year-end through reductions in materials, manufacturing, and freight costs. Chief Financial Officer John Lawler noted that pricing pressures are likely to persist, potentially offsetting cost gains.

Market Reactions and Competitor Insights

Ford’s stock has declined 6% this year, a relatively smaller drop than Jeep-manufacturer Stellantis, whose shares have fallen by 40%. Conversely, General Motors has led the “Big Three” automakers in stock performance, with shares up 47% following robust earnings and consistently improved financial guidance.

 

Novo Nordisk Shares Dip Amid Earnings Miss and Reduced Profit Outlook

/in /tarafından

Novo Nordisk experienced a dip in its share price after posting weaker-than-expected net profit for the second quarter and revising its operating profit outlook downwards. The pharmaceutical giant reported a net profit of 20.05 billion Danish kroner ($2.93 billion) for the quarter ending in June, falling short of the 20.9 billion Danish kroner projected by LSEG analysts. Additionally, the company’s EBIT (earnings before interest and tax) was 25.93 billion Danish kroner, below the forecasted 26.86 billion Danish kroner.

In response to these results, Novo Nordisk adjusted its full-year 2024 operating profit growth expectations to a range of 20% to 28%, down from the previous 22% to 30%. This announcement caused the company’s shares to tumble nearly 7% before recovering slightly, trading down 2.71% by 9:40 a.m. London time.

Despite the disappointing second-quarter earnings, Novo Nordisk raised its sales growth guidance for the full year, expecting growth between 22% and 28% at constant exchange rates, up from the previous estimate of 19% to 27%. This optimism is partly driven by a 55% increase in sales of its popular weight loss drug, Wegovy, which reached 11.66 billion kroner in the second quarter compared to the same period in 2023.

CEO Lars Fruergaard Jørgensen expressed confidence in the company’s future growth, highlighting the potential for “attractive growth” in the coming months. He assured investors of the company’s ability to scale operations and supply patients, emphasizing that adjustments to rebates were a factor in the second-quarter results. Jørgensen remains positive about the long-term competitiveness of Novo Nordisk, even in the face of increasing competition from companies like Roche, which recently reported promising early-stage trial data for its obesity drug candidate.

Moreover, Novo Nordisk’s Wegovy has recently achieved significant milestones. The drug was approved for sale in China, the world’s second-largest economy, and received backing from medical regulators in the U.K. and European Union for reducing risks of serious heart events among overweight and obese adults.